Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

NCT03816891 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Prurigo Nodularis
Pruritis

Interventions

DRUG: Vixarelimab
DRUG: Placebo

Sponsor

Genentech, Inc.

Collaborators

[object Object]